Gender Selection As Part Of Advanced Reproductive Technology: Does The U.S. Prefer Boys Or Girls?
By Amy Schaeffer,
The Inquisitr
| 04. 09. 2016
[citing CGS' Marcy Darnovsky]
Untitled Document
While most people aren’t extremely concerned about what gender child they have, it’s becoming more and more important to some – partly due to the balancing of families, and sometimes due to health issues which only are present in male or female children. Whatever the reason, there has been an increase in people seeking gender selection of their child using advanced reproductive technologies. This is legal in the United States, but is forbidden for religious, ethical, and cultural reasons in many countries, which cause some individuals from other countries to seek this service in the United States, with nobody in their home country being any wiser for it.
A report from The Charlotte Observer says that about one in every eight U.S. women of reproductive age and their partners who wish to become pregnant have difficulty getting pregnant, according to the American Society for Reproductive Medicine. That’s partly due to the fact that women are waiting longer than ever to start childbearing, partially because they want to have careers and relationships well under way before they become parents...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...